These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19079906)

  • 1. Therapeutic potential of curcumin in non-alcoholic steatohepatitis.
    Shapiro H; Bruck R
    Nutr Res Rev; 2005 Dec; 18(2):212-21. PubMed ID: 19079906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commonly used animal models of non-alcoholic steatohepatitis.
    Fan JG; Qiao L
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.
    Tsai J; Zhang R; Qiu W; Su Q; Naples M; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1287-98. PubMed ID: 19342510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats.
    Tahan V; Atug O; Akin H; Eren F; Tahan G; Tarcin O; Uzun H; Ozdogan O; Tarcin O; Imeryuz N; Ozguner F; Celikel C; Avsar E; Tozun N
    J Pineal Res; 2009 May; 46(4):401-7. PubMed ID: 19552763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy in NASH].
    Tokushige K
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and steatosis in humans.
    Capeau J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):649-57. PubMed ID: 19195626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C.
    Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A
    Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
    Ali R; Cusi K
    Ann Med; 2009; 41(4):265-78. PubMed ID: 19353360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells.
    Wobser H; Dorn C; Weiss TS; Amann T; Bollheimer C; Büttner R; Schölmerich J; Hellerbrand C
    Cell Res; 2009 Aug; 19(8):996-1005. PubMed ID: 19546889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
    Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
    J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L; Lemoine M
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver NF-kappaB and AP-1 DNA binding in obese patients.
    Videla LA; Tapia G; Rodrigo R; Pettinelli P; Haim D; Santibañez C; Araya AV; Smok G; Csendes A; Gutierrez L; Rojas J; Castillo J; Korn O; Maluenda F; Díaz JC; Rencoret G; Poniachik J
    Obesity (Silver Spring); 2009 May; 17(5):973-9. PubMed ID: 19165171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis.
    Fujita N; Miyachi H; Tanaka H; Takeo M; Nakagawa N; Kobayashi Y; Iwasa M; Watanabe S; Takei Y
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):424-32. PubMed ID: 19190144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of curcumin: problems and promises.
    Anand P; Kunnumakkara AB; Newman RA; Aggarwal BB
    Mol Pharm; 2007; 4(6):807-18. PubMed ID: 17999464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.
    Remels AH; Langen RC; Gosker HR; Russell AP; Spaapen F; Voncken JW; Schrauwen P; Schols AM
    Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E174-83. PubMed ID: 19417127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin ameliorates hepatic fibrosis in type 2 diabetes mellitus - insights into its mechanisms of action.
    Stefanska B
    Br J Pharmacol; 2012 Aug; 166(8):2209-11. PubMed ID: 22452372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.